Arthritis & Rheumatology is a leading journal dedicated to the advancement of knowledge in the fields of rheumatology, immunology, and allergy. Published by WILEY in the United Kingdom, this prestigious journal boasts an impressive impact factor and a prominent reputation, ranking in the Q1 category across multiple disciplines, including Immunology and Rheumatology. With its high ranking of 4th out of 73 in Rheumatology and notable standings in related fields, it serves as a crucial platform for researchers, healthcare professionals, and scholars to disseminate groundbreaking findings. The journal embraces an Open Access model, enhancing the accessibility of vital research to a global audience and ensuring that knowledge dissemination is maximized. Since its inception in 2014, Arthritis & Rheumatology has been at the forefront of impactful research, fostering collaboration and innovation in tackling complex challenges within these medical disciplines. Researchers looking to explore the latest advancements and engage with cutting-edge studies in these fields will find this journal to be an essential resource.

Current Treatment Options in Rheumatology, published by SPRINGERNATURE, is a pivotal journal focused on advancing the field of rheumatology through the dissemination of cutting-edge research and comprehensive reviews. With an emphasis on current therapeutic strategies, this journal aims to provide healthcare professionals, researchers, and students with up-to-date information on the latest treatment modalities for rheumatic diseases. Although it operates under a subscription model, it offers a platform for sharing significant findings that can influence clinical practice and policy within the field of rheumatology. By promoting insightful discussions and collaborations, Current Treatment Options in Rheumatology plays a crucial role in shaping the future of rheumatic disease management and improving patient outcomes.

ACR Open Rheumatology, published by WILEY, is a premier open-access journal dedicated to advancing the field of rheumatology. Since its inception in 2019, this journal has rapidly gained recognition, achieving a Q1 category ranking in the 2023 Scopus Quartiles, positioning it among the top 30% within its discipline. With a current Scopus rank of 22 out of 73 in Medicine - Rheumatology and an impressive 70th percentile, ACR Open Rheumatology serves as a vital platform for researchers and clinicians to disseminate knowledge on the latest developments in rheumatic diseases and treatments. The journal promotes unrestricted access to cutting-edge research, thus fostering collaboration and innovation in the rheumatological community. Situated in the United States, it caters to a global audience, encouraging submissions from researchers worldwide and addressing critical health issues that affect millions. We invite professionals, students, and researchers alike to engage with the transformative findings published in our journal.

Acta Reumatologica Portuguesa is a premier open access journal dedicated to the field of rheumatology and general medicine, published by PUBLISAUDE-EDICOES MEDICAS LDA since its inception in 1973. Situated in Portugal, this journal aims to disseminate high-quality research findings, clinical studies, and reviews that contribute to the understanding and management of rheumatic diseases. Despite its current Q4 ranking in both Medicine (miscellaneous) and Rheumatology, it serves as a vital platform for researchers and professionals aiming to share innovative insights and clinical practices within a rapidly evolving field. Researchers and medical professionals will find valuable information that can significantly influence their work, given the journal’s commitment to accessible knowledge through its open access model. By prioritizing collaboration and knowledge-sharing, Acta Reumatologica Portuguesa continues to engage with issues of critical relevance in rheumatology, appealing to a diverse audience of scholars and healthcare practitioners.

Rheumatology International, published by Springer Heidelberg, is a prestigious journal that focuses on innovative research in the field of rheumatology and immunology. Established in 1981, this peer-reviewed journal has contributed significantly to advancing our understanding of autoimmune disorders, clinical approaches, and therapeutic interventions. It holds a commendable Q2 ranking in the categories of Immunology, Immunology and Allergy, and Rheumatology as of 2023, showcasing its influence and importance within these disciplines. With a robust Scopus ranking—positioned 14 out of 73 in Medicine Rheumatology—it caters to a diverse audience of researchers, clinicians, and students committed to improving patient care and treatment modalities. Although it does not currently offer open access options, the journal remains a vital resource for insights on contemporary challenges and breakthroughs in rheumatological research, published from its base in Heidelberg, Germany.

Current Rheumatology Reviews is an esteemed journal dedicated to publishing comprehensive reviews on advancements in the field of rheumatology. Established by Bentham Science Publishers, this journal has become a vital resource for researchers, clinicians, and students seeking to stay abreast of the latest developments and therapeutic strategies from 2006 to 2024. Located in the United Arab Emirates, it caters to a global audience, delivering insights that have been pivotal in shaping clinical practices. With an impact factor reflective of its Q3 status in Rheumatology by 2023, the journal ranks #46 out of 73 in the Scopus database, positioning it in the 37th percentile in the discipline. Although it operates without open access, its high-quality content ensures that each article undergoes rigorous peer review, making the Current Rheumatology Reviews a trusted platform for disseminating critical research findings and reviews that drive forward the understanding and treatment of rheumatic diseases.

Open Access Rheumatology-Research and Reviews, published by DOVE MEDICAL PRESS LTD, is a distinguished journal that has been a vital part of the rheumatology field since its inception in 2009. With an ISSN of 1179-156X, this journal is dedicated to disseminating groundbreaking research and comprehensive reviews in the discipline of rheumatology, making it an essential resource for researchers, clinicians, and students alike. It boasts an impressive Q3 ranking in the Rheumatology category for 2023, reflecting its relevance and quality within a highly competitive landscape, where it ranks in the 51st percentile among its peers as indicated by the Scopus Ranks. As an open-access platform, it ensures that critical findings and insights are easily accessible to a global audience, promoting collaboration and knowledge sharing. The journal's scope includes a wide range of topics within rheumatology, aimed at advancing understanding and treatment of musculoskeletal disorders and autoimmune diseases. Its headquarters is located in New Zealand, positioning it as a key player in the international research community.

Dermatology and Therapy is a prestigious Open Access journal, published by ADIS INT LTD since 2011, that has quickly established itself as a vital resource in the field of dermatology. With an impressive Q1 ranking in the Dermatology category as of 2023 and a commitment to disseminating high-quality research, this journal fosters innovation and knowledge exchange among professionals, researchers, and students alike. Its broad scope encompasses the latest advancements in dermatological therapies, contributing significantly to both clinical practice and academic research. Based in Germany and operating under a global perspective, Dermatology and Therapy provides an essential platform for open access research, encouraging unrestricted access to groundbreaking studies and fostering collaboration across borders. Join the community of dermatology experts by exploring the wealth of knowledge available in this influential journal.

The Lancet Rheumatology, published by Elsevier, is a premier academic journal dedicated to advancing the understanding of rheumatology and immunological diseases. Launched in 2019, this esteemed publication has quickly become a leading source of research, achieving an impressive Q1 ranking in both the fields of Rheumatology and Immunology as of 2023. With Scopus rankings placing it at #2 out of 73 in Medicine - Rheumatology and #6 out of 233 in Medicine - Immunology and Allergy, the journal serves as an essential platform for disseminating high-quality, peer-reviewed articles that address the latest findings and clinical practices in these domains. The journal, accessible in print and online, is committed to fostering knowledge and collaboration among researchers, healthcare professionals, and students alike, making it an invaluable resource for those seeking to deepen their expertise in rheumatology and its interrelated fields.

JCR-Journal of Clinical Rheumatology, published by Lippincott Williams & Wilkins, is a premier outlet dedicated to the field of rheumatology, recognized for its contributions and relevance among medical journals. Boasting an impact factor reflective of its vital role in disseminating innovative research, it currently holds a Q2 category ranking in Medicine (miscellaneous) and a Q3 ranking in Rheumatology as of 2023. With its convergence years spanning from 1995 to 2024, the journal aims to foster the advancement of knowledge in clinical practices, therapeutic advances, and patient management strategies concerning rheumatic diseases. Researchers, professionals, and students can access a wealth of benchmark studies and peer-reviewed articles, enhancing their understanding and collaboration within this dynamic field. By bridging clinical insights with rigorous research, the JCR-Journal of Clinical Rheumatology remains an important resource for advancing the understanding of rheumatologic disorders and improving patient care.